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Abstract
Background: Visceral leishmaniasis caused by members of the Leishmania donovani complex is
often fatal in the absence of treatment. Research has been hampered by the lack of good laboratory
models and tools for genetic manipulation. In this study, we have characterised a L. infantum line
(JPCM5) that was isolated from a naturally infected dog and then cloned. We found that JPCM5 has
attributes that make it an excellent laboratory model; different stages of the parasite life cycle can
be studied in vitro, it is accessible to genetic manipulation and it has retained its virulence.
Furthermore, the L. infantum JPCM5 genome has now been fully sequenced.
Results: We have further focused our studies on LiCPA, the L. infantum homologue to L. mexicana
cysteine peptidase CPA. LiCPA was found to share a high percentage of amino acid identity with
CPA proteins of other Leishmania species. Two independent LiCPA-deficient promastigote clones
(∆Licpa) were generated and their phenotype characterised. In contrast to L. mexicana CPA-deficient
mutants, both clones of ∆Licpa were found to have significantly reduced virulence in vitro and in vivo.
Re-expression of just one LiCPA  allele (giving ∆Licpa::CPA) was sufficient to complement the
reduced infectivity of both ∆Licpa mutants for human macrophages, which confirms the importance
of LiCPA for L. infantum virulence. In contrast, in vivo experiments did not show any virulence
recovery of the re-expressor clone ∆LicpaC1::CPA compared with the CPA-deficient mutant
∆LicpaC1.
Conclusion:  The data suggest that CPA is not essential for replication of L. infantum
promastigotes, but is important for the host-parasite interaction. Further studies will be necessary
to elucidate the precise roles that LiCPA plays and why the re-expression of LiCPA in the ∆Licpa
mutants complemented the gene deletion phenotype only in in vitro and not in in vivo infection of
hamsters.
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Background
Leishmania species are responsible for several pathologies
affecting both humans and animals. These parasites are
most abundant in developing countries in the Middle
East, Asia and South America but also are endemic in the
Sub-Mediterranean basin. They have emerged as one of
the most important opportunistic agents in AIDS patients
[1]. Some cutaneous infections can be resolved and subse-
quently lead to the development of protection against
new infection. These results indicate that immunologic
approaches could be effective in preventing or curing
infection [2]. However, an effective and safe vaccine has
yet to be developed. Efforts towards the development of
new cures or vaccines have recently been facilitated by the
sequencing of L. major [3], L. braziliensis and L. infantum
genomes.
L. infantum is a member of the L. donovani complex, which
is primarily responsible for life-threatening visceral leish-
maniasis. These parasites differ significantly from L. major
and L. mexicana, species causing cutaneous leishmaniasis
that are classified as Old-world and New-world, respec-
tively, based on their geographical distribution. L. infan-
tum is present in both Europe and the Americas, where it
has been named L. chagasi [4]. Whilst there has been some
debate about whether L. infantum originated in the Old
World or the New World, it has been proposed that L.
infantum and L. chagasi are essentially genetically indistin-
guishable [5]. L. infantum can infect humans and dogs,
causing zoonotic visceral leishmaniasis in children and
immunosuppressed adults as well as canine visceral leish-
maniasis (CanL) [1,4]. CanL is a severe disease that can be
fatal if left untreated. Current treatment is complicated
and expensive and generally does not result in complete
cure. A vaccine would be an important tool in the preven-
tion of CanL and, as dogs are the prime reservoir species
for L. infantum, could also reduce the incidence of human
visceral leishmaniasis [6].
The sequencing projects for Leishmania  [3] and other
trypanosomatids [7,8] have led to the identification of
many Leishmania-specific genes that potentially might be
exploited for vaccine and drug design [9,10]. Moreover,
additional candidates are likely to be identified as the cur-
rently unidentified gene products are ascribed a function
[3]. However, validation or rejection of a protein as a
potential vaccine or chemotherapeutic target requires sig-
nificant experimental investigations that are time-con-
suming. Thus decisions upon priorities for study are
crucial. Investigating the extent to which key proteins are
conserved between Leishmania species is one primary con-
sideration, as currently it is unclear to what extent knowl-
edge acquired from one Leishmania species can be applied
to other species. This has important practical applications,
as the leishmanias are not all geographically distinct and
some virulence factors, when used as a vaccine, have been
shown to exhibit distinct protective ability between mem-
bers of L. donovani complex and L. major [11-13]. The
recent completion of the sequencing of the L. infantum
and L. braziliensis genomes and comparison of these with
that of L. major has facilitated analyses of gene/protein
conservation but also it has revealed Leishmania species-
specific genes and proteins that could be key mediators of
species-specific disease phenotypes.
Cysteine peptidases (CPs) have been characterised as vir-
ulence factors and vaccine candidates in Leishmania [14-
18]. L. mexicana possesses three families of related CPs
encoded by single (CPA and CPC) or multicopy (CPB)
genes [19-21]. While gene deletions of LmxCPB, and to a
lesser extent LmxCPC, lead to an attenuated phenotype,
null mutants for LmxCPA exhibited no apparent change in
phenotype [14]. However, the double null mutant for
LmxCPB and LmxCPA did not induce any lesions in Balb/
C mice and the ability of this line to induce an immune
response in mice suggested that it has potential as an
attenuated live vaccine [14,22].
In order to assess the level of conservation in both struc-
ture and function of these CPs between Leishmania spe-
cies, we have initiated a characterisation of cysteine
peptidase orthologues in a cloned L. infantum line
(JPCM5) derived from a recent isolate from a naturally
infected dog in Spain. To validate the usefulness of JPCM5
for this and other experimental studies, we have tested
whether the clone has the essential characteristics for a
laboratory model: that it causes visceral leishmaniasis in
experimental animals and is accessible to most experi-
mental studies including reproduction of its life cycle in
vitro  and genetic manipulation. We present here the
results of this analysis and the use of the clone for a molec-
ular study on LiCPA.
Results
Isolation and characterisation of L. infantum JPCM5
Leishmania  parasites were recovered from a naturally
infected dog from the Madrid area, Spain. They were char-
acterised as L. infantum zymodeme 1 (MON-1) by isoen-
zyme analysis [23] and transformed into promastigotes in
vitro  before being stored under liquid nitrogen as JPC
(MCAN/ES/98/LLM-724). Five independent clones
(JPCM1 to JPCM5) were derived from this stock by colony
cloning and tested for infectivity in hamsters. Two of the
cell lines were recovered from the spleen 15 weeks after
infection confirming that they had conserved their infec-
tion potential. Clone M5 (JPCM5; MCAN/ES/98/LLM-
877) was selected for all further studies.
JPCM5 grew well as promastigotes in vitro in many of the
media used to grow Leishmania, including RPMI, SDM79BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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and NNN. A temporary increase of serum concentration
from 10 to 20% (v/v) promoted the parasite's growth fol-
lowing adaptation to a different medium, cloning, trans-
formation from, or to, amastigotes and transfection
experiments. In HOMEM medium with 10% (v/v) serum,
the parasites had a doubling time of 16.0 ± 2.7 h. After 4
to 5 days in culture, when stationary phase had been
reached, most promastigotes had a metacyclic morphol-
ogy, indicating that metacyclogenesis had occurred. Sta-
tionary phase promastigotes of JPCM5, grown in
HOMEM medium, were transformed in vitro into amastig-
ote-like forms using conditions previously described for
other L. infantum lines [24]. The transformation of the
entire culture, according to morphological parameters,
required 3 to 4 days at 37°C in acidic medium (pH 5.5 for
SDM or pH 6.5 for MAA). This was accompanied by
changes in protein profile as determined by SDS-PAGE
(data not shown). The axenic amastigotes could be main-
tained, with the help of regular sub-passages, or trans-
formed back into promastigotes by switching the culture
conditions to 28°C in HOMEM medium with 10% (v/v)
FCS. It generally required four days for transformation
fully back to promastigotes.
L. infantum JPCM5 were infective to human and dog mac-
rophages (see below) and hamsters. JPCM5 parasites
could be recovered from spleen, liver and bone marrow of
infected hamsters less than two months post infection.
Long-term in vitro culture of some Leishmania species has
been reported to result in loss of virulence [25]. To test
whether this applied to JPCM5, promastigotes were sub-
passaged in vitro for 8, 17 and 25 weeks (corresponding to
about 10, 20 and 30 sub-passages, respectively) before
being inoculated into hamsters. In each case, amastigotes
were recovered from the spleen after less than three
months indicating that the promastigotes had not lost
their virulence and were still able to establish an infection.
These in vitro and in vivo results indicated that JPCM5 is
suitable for most cell-culture studies.
Isolation of the CPA cysteine peptidase gene
The complete CPA gene of L. infantum JPCM5 (LiCPA),
including the ORF and the 5' and 3' flanks, was amplified
by PCR using primers derived from the L. mexicana CPA
[21] and sequenced. The LiCPA ORF sequence predicted a
protein of 354 amino acids corresponding to a size of 38.9
kDa, an isoelectric point of 7.6 and possessing a 10 amino
acid C-terminal extension similar to the L. mexicana CPA
[21]. Comparison of the deduced amino acid sequence
with the translated CPA sequences from several Leishma-
nia  species is shown in Figure 1. LiCPA shares 97.7%
amino acid identity with the published L. chagasi CPA
(LcCPA) [26], 87.3% with L. major CPA (LmjCPA) and
80.3% with L. mexicana CPA (LmxCPA) protein
sequences, respectively. There are three potential N-glyco-
sylation sites in LiCPA, two in the mature domain
(208NGT210 and 170NHS172) and one at the beginning of
the C-terminal extension (345NTS347); the last two being
conserved in all sequences except in L. mexicana and L.
braziliensis. However, amino-acid residues important for
catalysis,  153C,  289H and 309N, as well as the predicted
glutamine of the oxyanion hole 147Q, are conserved in all
sequences [21]. LiCPA is identical in size to CPA from L.
major,  L. mexicana and  L. donovani, but differs from
LbCPA, which has a 123 amino acid C-terminal exten-
sion. A C-terminal extension is characteristic of the cathe-
psin L-like CPB cysteine peptidases of Leishmania  and
other trypanosomatids [20,27], but has not been
observed before in any CPA protein.
Southern blot analysis showed that LiCPA is single-copy
(Figure 2, panels A and B) and Northern blotting showed
that LiCPA is expressed at similar levels in log phase and
stationary phase promastigotes and also amastigotes (Fig-
ure 2C). A LiCPA deletion construct containing the SAT
gene flanked by about 800 bp of LiCPA 5' and 3' flank
regions was generated and used to transfect JPCM5 para-
sites. The parasites were selected in 96-well plates with
HOMEM medium supplemented with the antibiotic
nourseothricin. In these conditions, one clone was
obtained seven weeks post-transfection. Southern blot
analysis (Figure 3B) and PCR analyses (Figure 4A) showed
correct integration of the SAT construct into the LiCPA
locus. Moreover, the wild type alleles could not be ampli-
fied with CPA gene specific primers (Figure 4A), and CPA
mRNA could not be detected (Figure 4C), confirming that
this nourseothricin-resistant clone (named ∆LicpaC1) is a
null mutant resulting from loss of heterozygocity.
A second transfection was performed on JPCM5 promas-
tigotes with a second deletion construct derived from the
previous one by replacement of the SAT marker by the BLE
gene. The transfection and selection steps were performed
as previously, except that 10 µg/ml of phleomycin was
used in place of nourseothricin. Four clones grew onto
agar plates after two weeks. PCR (Figure 4A) and Southern
blot (not shown) analysis demonstrated that these four
clones were ∆Licpa heterozygote mutants having correctly
integrated the BLE construct into one LiCPA allele. One of
these (clone 3047) was selected and re-transfected with a
third CPA knockout construct, pGL813, carrying the HYG
gene. A total of 16 clones were obtained from four 96-well
plates after two weeks of selection in the presence of both
phleomycin and hygromycin. Southern analysis of one of
these clones, called ∆LicpaC2, confirmed that it was
indeed a hygromycin- and bleomycin-resistant ∆Licpa
null mutant (Figure 3C) and RT-PCR analysis of cDNA
showed the absence of CPA mRNA (Figure 4C). The
LiCPA gene was re-introduced into the CPA locus in both
∆Licpa mutants. The re-integration construct, pGL793,BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
Page 4 of 13
(page number not for citation purposes)
Alignment of CPA amino acid sequences Figure 1
Alignment of CPA amino acid sequences. Alignment of deduced amino acid sequence of LiCPA (CAD12932) from L. infan-
tum JPCM5, with deduced amino acid sequences obtained from GenBank. These included L. major (LmjCPA, CAC18865.1), L. 
mexicana (lmxCPA, CAA44094), L. donovani (LdCPA, AAK27384.1), L. chagasi (LdcCPA, AAC38833) and L. braziliensis (LbCPA, 
LbrM19.1180). The dots represent amino acid identity. The arrows show the predicted cleavage sites of pro/mature domains 
and mature/C-terminal extension, respectively. Amino acid residues important for the catalysis are indicated as follows : active 
site cysteine C153 (), the predicted catalytic dyads H289 and N309 (● ) and the predicted glutamine of the oxyanion hole Q147 
(▼ ). The potential glycosylation sites are shown in boxes.
LiCPA     1 MARRNPFFFAIVVTIRFVVCYGSALIAQTPLGVVDFIASAHYGRFKKRHGKPFGEDAEEG 
LmjCPA    1 .......L.......L.........V.......DN...........E....S.....D.. 
LmxCPA    1 ......LL.......L..............PP.DN.V......S.......A..G..... 
LdCPA     1 ...............L.................D.......................... 
LdcCPA    1 ...-...........L.................D.......................... 
LbCPA     1 ......LL..M.A.VL.AL..C.TV..R.LH.ID.EV....FMH...Q...S...E.V.. 
LiCPA    61 RRFNAFKQNMQTAYFLNAHNPHAHYDVSGKFADLTPQEFAKLYLNPNYYARHGKDYKEHV 
LmjCPA   61 H................T............................D...HR........ 
LmxCPA   61 H................TQ...........................D.....L.NH..D. 
LdCPA    61 ............................................................ 
LdcCPA   60 ............................................................ 
LbCPA    61 H......E.....VY...Q.............A........Q....D..T.QL.AH..RA 
LiCPA   121 HVDDSVRSGVMSVDWREKGVVTPVKNQGMCGSCWAFATTGNIEGQWALKNHSLVSLSEQV 
LmjCPA  121 ......L..A.........A................SAI....S...............M 
LmxCPA  121 .....AP.........D..A........L.......SAI........ASG.........M 
LdCPA   121 ............................................................ 
LdcCPA  120 ............................................................ 
LbCPA   121 ..YEG..G.LSA.......A..E..D..L.......SAI.........SGNT.......M 
LiCPA   181 LVSCDNIDDGCNGGLMQQAMQWIINDHNGTVPTEDSYPYTSAGGTRPPCHDNGTVGAKIK 
LmjCPA  181 .....D..........D...E...QH........K....A.....S.....K.EF..R.S 
LmxCPA  181 ........E.......D...N..MQS...S.F..A......G.........E.E.....T 
LdCPA   181 ................E..........................................A 
LdcCPA  180 ...........................................................A 
LbCPA   181 .....TV.M.......D..WA...KN.S.A.Y..V......GD.STAS.LST.K...R.S 
LiCPA   241 GYMSLPHDEEEIAAYVGKNGPVAVAVDATTRQLYFGGVVTLCFGLSLNHGVLVVGFNRQA 
LmjCPA  241 .........KA.....E.K...........W..........................KR. 
LmxCPA  241 .FL.......R..EW.E.R...........W........S..LAW.......I....KN. 
LdCPA   241 ..............................W............................. 
LdcCPA  240 ..............................W............................. 
LbCPA   241 .QV...Q..DA.E.WLE....ISI......W........SN..AY.N......L..Y.NS 
LiCPA   301 KPPYWIVKNSWGSSWGEKGYIRLAMGSNQCLLKNYVVTATIDDSNTSHVPTTAA 354 
LmjCPA  301 ............T......................P....V...........T. 354 
LmxCPA  301 ..............................M....P.S..VESPH.P.....T. 354 
LdCPA   301 ...................................A.................. 354 
LdcCPA  300 ...................................A.................. 353 
LbCPA   301 N...........T....H......K.....MM.D.AMS..VGGTT..RA...TEAPKPSE 
Ɣ
ź ¸
Ɣ
LbCPA   361 TVLVQKKCLLNGCSRLCTSTTYPTGVCLRRRGGGSVMVTCQEEEVVELIFRSSSCSGNSQ 
LbCPA   421 ETRMPLNQCMPSYMGYFQNICASSVGAGSTSDPISDLSRPLLLGQPGVPAATHEGIIQH 479BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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contained the LiCPA ORF surrounded by the native 5'
flank with 3' sequence derived from the DHFR locus, and
the blasticidin-resistance gene enclosed between the 5'
and 3' DHFR flank sequences. Both ∆Licpa mutants were
transfected with the re-integration cassette and selection
achieved in the presence of 10 µg/ml of blasticidin. Sev-
eral clones were isolated from each transfection (the ones
characterised in this study were named ∆LicpaC1::CPA
and∆LicpaC2::CPA) and the correct replacement of previ-
ously integrated deletion cassettes was confirmed by PCR
(Figure 4A) and Southern blot (Figure 4B). LiCPA re-
expression in ∆LicpaC1 and ∆LicpaC2 was demonstrated
by RT-PCR (Figure 4C).
The ∆LicpaC1 and ∆LicpaC2 mutants were grown as pro-
mastigotes in HOMEM medium. In these conditions, they
exhibited no apparent growth reduction compared with
wild type JPCM5. They were also both able to transform
into axenic amastigotes. In order to assess whether the
mutants lacking CPA were virulent, their infectivity
toward human macrophages was investigated. In compar-
ison with JPCM5, the ∆LicpaC1 and ∆LicpaC2 mutants
had a reduced ability to infect human macrophages (Fig-
ure 5A) and a reduced number of amastigotes/infected
macrophage (Figure 5B). The infectivity was restored to
wild type levels by re-expression of CPA in the ∆LicpaC2
mutant, but ∆LicpaC1::CPA  had a virulence phenotype
midway between the ∆LicpaC1 mutant and wild type par-
asites. Some cell lines were also tested for their ability to
infect macrophages of dogs (Figure 5C and 5D). No statis-
tically significant differences (ANOVA; p ≤ 0.05) were
observed between wild type, ∆LicpaC1 or∆LicpaC1::CPA
with respect to percentage of infected macrophages or the
number of amastigotes per infected macrophage.
The virulence of ∆LicpaC1 to hamsters was found to be
significantly less than for the wild type JPCM5. In a ham-
ster infection model (Figure 6) parasites were not detected
in the liver and only very low levels were detected in the
spleen, with the number of parasites decreasing between
1 and 6 months post-infection. The overall parasite bur-
den for these clones was between 102- and 104-fold lower
compared with JPCM5 at 1 and 6 months post-infection,
respectively. The virulence of ∆LicpaC1::CPA  was also
compared in vivo to JPCM5. Low numbers of parasites
were found in the spleen of ∆LicpaC1::CPA infected ham-
sters 3 months post-infection, whereas no parasites were
detected in spleen or liver of hamsters at other time
points, indicating the virulence was not restored in the re-
expresser clones.
Discussion
L. major was the first Leishmania species to have its genome
sequenced [3]. For comparative genomics, it was thought
that the second Leishmania  species to have its genome
sequenced should be a causative agent of visceral leishma-
niasis. There are several closely-related species of the L.
donovani species complex that are found in different geo-
graphical regions. L. donovani is the primary cause of vis-
ceral leishmaniasis in the Indian subcontinent and East
Africa, L. infantum in the Mediterranean region and L. cha-
gasi in the New World. Humans are the only known reser-
voir of L. donovani in India, while canines, especially
domestic and stray dogs, provide the main reservoir host
for L. infantum and L. chagasi [4]. While the last two spe-
cies are considered to be genetically identical [4], all three
are very similar. Based on gene sequencing and microsat-
ellite analysis (the most sensitive method currently avail-
able for discriminating between populations), recent
studies have been unable to separate East African L. dono-
vani strains from L. infantum [28,29]. These African strains
are also very close to the Indian L. donovani strains. Thus,
it could be argued that whichever L. donovani complex
LiCPA genomic organisation and expression Figure 2
LiCPA genomic organisation and expression. A) Map of 
LiCPA locus with the different subclones analysed indicated. 
B) Southern blot of L. infantum JPCM5 gDNA hybridized with 
the LiCPA PCR product. The gDNA was digested using SphI 
(lane 1), PstI (lane 2), XhoI (lane 3), SmaI (lane 4), SacI (lane 5) 
and ApaI (lane 6). C) Northern blot of total RNAs from 
L.infantum JPCM5 log phase promastigotes (P), stationary 
phase promastigotes (S) and axenic amastigotes (A) hybrid-
ized with the LiCPA ORF PCR product. After washing, the 
membrane was exposed on a phosphor-activated screen. An 
ethidium bromide-stained gel of RNA samples for each life 
cycle stage is shown in the lower panel.
3.8 kb 3.8 kb A)
I I I LiCPA PstI 5'FR 3'FR Pst LiCPA Pst PstI I 5'FR 5'FR 3'FR 3'FR Pst Pst LiCPA
1 kb
pGL504
pGL744
ORF prod.
pGL504
pGL744 pGL744
pGL504
1 kb 1 kb
kb
21
3.5
5.1
4.1
1    2    3  4     5 6
B)
C) AS   P AS   PBMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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Generation of Licpa null mutants Figure 3
Generation of Licpa null mutants. A) PstI restriction map of ∆LicpaC1, ∆LicpaC2 and ∆LicpaC1::CPA loci. The size of the 
restriction fragments expected is indicated. 5'FR and 3'FR indicate the 5' and 3' LiCPA flank sequence, respectively. The arrow-
heads indicate the position of the different primers used to confirm the correct integration of the disruption constructs by 
PCR. B) Southern blot analysis of the ∆LicpaC1 mutant DNA digested with PstI and hybridized with the following probes : LiCPA 
3'FR (lane A), ORF (lane B) and 5'FR (lane C). Lane D shows L. infantum DNA hybridized with the 3'FR probe. C) Southern blot 
analysis of ∆LicpaC2 mutant (lane A) and wild type (lane B) DNA hybridized with the LiCPA 5'FR probe. The single and double 
arrowheads indicate the deleted and the wild-type alleles, respectively.
A)
B)C )
∆LicpaC1 locus :
∆LicpaC1::CPA locus 
:
∆LicpaC2 loci :
3 -
2 -
4 -
A       B       C      D
kb
3 -
2 -
4 -
1.6 -
A           B
-3
-2
-4
-- 1.6
-3
-2
-4
kb
1 kb
OL907 OL17 OL320
Sat 5'FR 3'FR
3.4 kb
PstI PstI PstI
OL1027
2.1 kb
OL907 OL17 OL320
Sat 5'FR 3'FR
3.4 kb
PstI PstI PstI
OL1027
2.1 kb
2.1 kb 3.25 kb
5'FR PstI PstI Ble 3'FR PstI
OL907 OL11 OL1027
OL1027
PstI PstI 5'FR
Hyg
3'FR PstI PstI
3.15 kb 2.1 kb 0.8 kb
OL907 OL13 OL14
2.1 kb 3.25 kb
5'FR PstI PstI Ble 3'FR PstI
OL907 OL11 OL1027
2.1 kb 3.25 kb
5'FR PstI PstI Ble 3'FR PstI
OL907 OL11 OL1027
OL1027
PstI PstI 5'FR
Hyg
3'FR PstI PstI
3.15 kb 2.1 kb 0.8 kb
OL907 OL13 OL14 OL1027
PstI PstI 5'FR
Hyg
3'FR PstI PstI
3.15 kb 2.1 kb 0.8 kb
OL907 OL13 OL14
LiCPA Bsd 5'FR 3'FR
probe
2.7 kb 3.3 kb
PstI PstI PstI
OL67       OL64
LiCPA Bsd 5'FR 3'FR
probe
2.7 kb 3.3 kb
PstI PstI PstI
OL67       OL64BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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Analysis of Licpa null mutants Figure 4
Analysis of Licpa null mutants. A) PCR analysis of the two ∆Licpa mutants. PCR reactions were performed using primers 
indicated in Figure 3A. WT: wild-type, H; heterozygote CPA/∆Licpa, ∆C1: ∆LicpaC1 and ∆C2: ∆LicpaC2. B) Southern blot analy-
sis of the ∆LicpaC1 (lane A) and ∆LicpaC1::CPA (lane B) re-expresser mutant DNA digested with PstI and hybridized with a 5'FR 
probe. C) RT-PCR analysis of wild type (WT), ∆LicpaC1 (∆C1), ∆LicpaC1::CPA (∆C1:CPA), ∆LicpaC2 (∆C2) and ∆LicpaC2::CPA 
(∆C2:CPA) parasites. Nested PCR were carried out in presence (+) or in absence (-) of cDNA using the primer pairs OL136/SL 
primer. Lower panel is a control with the LinJ36.2050 gene.
A)
B)
C)
cDNA
WT
0.4
0.5
0.8
1.0
1.6
CPA
LinJ36.205
kb 'C2 'C1 'C2:CPA 'C1:CPA
++ +++
'C1
3 - 
2 - 
1.5 - 
1 - 
0.5 - 
WT kb
3 -
1 -
OL907 / OL11
2 -
1.5 -
H 'C2
kb
'C1 WT 'C1 'C1 kb kb
- 3 
- 2 
- 1.5 
- 3 
- 2 
- 1.5  - 1 
- 1 
- 0.5 
- 0.5 
OL320 /  OL907 /
OL1027 OL64
OL907 / OL17 OL67 / OL64
3-
2 - 
1.5 -
 OL14 /   OL907 /
OL1027    OL13 
H 'C2 'C2
1-
0.5 -
kb
3 - 
1.5 - 
WT 'C2
2 - 
1 - 
0.5 - 
kb
OL67 / OL64
B  A
2-
1.6 -
3-
5-
kb
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3-
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species was chosen for the genome project, the nucleotide
sequence data generated from the protein coding regions
would be likely to be almost identical. However, in order
to maximise the value arising from the genome sequenc-
ing, the parasite needs to be an experimentally amenable
organism.
The data resulting from the analyses described in this
paper show that L. infantum JPCM5 has the following
characteristics that make it a suitable line for many exper-
imental studies. It has been characterized as belonging to
zymodeme MON-1 by isoenzyme typing. MON-1 is one
of the most prevalent zymodemes in Europe and the Med-
iterranean basin, in countries such as Greece, France,
Spain, Italy, Algeria and Syria, and is also found in Brazil
[30-35]. JPCM5 has been shown to be virulent to ham-
sters (this study) and dogs [36], causing the symptoms of
visceral leishmaniasis in both animals. These observa-
tions are important as they show that the parasite has
maintained its virulence following isolation, cloning and
prolonged culture in the laboratory. The three major life-
cycle stages of JPCM5 can be grown in vitro. Importantly,
amastigotes can be propagated in vitro, and grown in
canine macrophages or human macrophages. We have
also shown that JPCM5 can be transfected successfully
with both integration (this study) and episomal (unpub-
lished) vectors. Transfected mutants can be cloned on soft
agar plates or by limiting dilution. The strain is therefore
suitable for genetic manipulation studies on genes identi-
fied from the genome project. JPCM5 maintains virulence
to animals after transfection and cell culture (> 2
LiCPA mutant infectivity in vivo Figure 6
LiCPA mutant infectivity in vivo. Hamsters were infected 
with wild type (WT), CPA null mutant (∆LicpaC1) or re-
expresser clone (∆LicpaC1::CPA) of L. infantum. The parasite 
burden in spleen and liver was determined by limiting dilution 
culturing at one, three and six months post infection (1, 3 or 
6 m.p.i.). Results are shown as the average parasite burden 
per group; error bars indicate the standard deviation.
LiCPA mutant infectivity in vitro Figure 5
LiCPA mutant infectivity in vitro. Human monocyte cells (U937) were 
infected with wildtype (WT), CPA null mutants (∆LicpaC1, ∆LicpaC2) or re-
expresser clones (∆LicpaC1::CPA, ∆LicpaC2::CPA) of L. infantum. Cell cultures 
were monitored for four days; results are presented as the percentage of 
infected macrophages and the number of amastigotes per infected cell in panels 
A and B, respectively. Similar experiments were performed in a canine mono-
cyte cell line (DH82) using WT, ∆LicpaC1 and ∆LicpaC1::CPA L. infantum clones. 
Cell cultures were monitored for five to ten days after infection; results are 
presented in panels C and D. Depicted values at 96 and 120 hrs incubation are 
the mean of four independent experiments and error bars indicate the standard 
deviation. The data for the ten day incubation period is derived from one 
experiment, hence the absence of a standard deviation.BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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months). This is important as it allows virulence studies to
be carried out on mutant parasites defective for virulence
genes. Many isolates of L. donovani lose their virulence
after transfection and prolonged culture, making it diffi-
cult to use this species for molecular genetic studies on vir-
ulence [25], thus the suitability of JPCM5 for such studies
is an important attribute. L. infantum JPC is infective for
sandfly vectors of the species Lutzomyia longipalpis [37],
one of the most widely available laboratory colonized
sandfly [38]. Finally, the L. infantum JPC isolate can be
successfully used as a challenge strain for vaccine studies
[36].
This study has confirmed through analysis of the CP CPA
that L. infantum JPCM5 is experimentally useful. Moreo-
ver, the investigation has provided important insight into
how the roles of proteins may differ between Leishmania
species. Our laboratory previously demonstrated that
cysteine peptidases are potent virulence factors in L. mexi-
cana [14,16]. Whilst L. mexicana ∆cpa mutants did not
show a defect in virulence in vivo [39], the ∆cpa/cpb double
mutants had a more defined virulence phenotype than
∆cpb – indicating that CPA plays an important role in this
parasite [14,22]. Virulence determinants are not always
conserved between species; for example the L. donovani
major antigen A2 was shown to not be expressed in L.
major [40]. Hence, we undertook the study of LiCPA to
determine how similar its role is in L. infantum and L. mex-
icana.
We deleted CPA in L. infantum and tested the mutants for
virulence  in vitro and in vivo. Two independent ∆Licpa
mutants were characterised in this study. The first mutant
generated, ∆LicpaC1, was the result of a loss of heterozy-
gocity, an event that has been reported to occur naturally
in response to an increase of drug concentration and
involves duplication of the allele carrying the antibiotic
resistance gene which leads to higher expression of the
gene product essential for parasite survival [41]. The sec-
ond mutant, ∆LicpaC2, was generated classically using two
independent markers and methods identical to the ones
used for L. mexicana [42]. For both mutants, molecular
analysis confirmed that the expected gene replacements
had taken place, so the ∆Licpa mutants could be consid-
ered genetically indistinguishable at the level of the
deleted LiCPA locus. Indeed both mutants exhibited an
attenuated phenotype, in vitro, in human macrophages,
and,  in vivo, in hamster infections. This indicates that
LiCPA might play a more important role in L. infantum
virulence than was found in the L. mexicana studies. These
findings were apparently not corroborated by dog macro-
phage experiments where ∆LicpaC1 was found as infective
as wild type parasites. However, the overall level of infec-
tion achieved – almost 12 times fewer dog macrophages
were infected than human macrophages with JPCM5
wild-type parasites – may have been too low to truly ana-
lyse the phenotype of ∆LicpaC1. On the other hand, the
number of amastigotes per infected macrophage was not
significantly different between wild type and mutant par-
asites, which suggests that LiCPA is not required for L.
infantum  survival in dog macrophages. One possible
explanation for the different behaviour of the parasites in
human and canine macrophage cell lines is the different
status of the host cells: the U937 human monocytes were
activated by PMA, whereas the DH82 canine monocytes
were not activated prior to addition of the parasites. The
low percentage of infection of the DH82 cells maybe due
to the non-activated status of the monocytes and conse-
quently differences in virulence between the parasite lines
would be harder to detect in such a system.
The finding that re-expression of only one LiCPA gene was
sufficient in itself to complement the reduced infectivity
of both LiCPA-deficient mutants for human macrophages
confirm the importance of LiCPA for L. infantum virulence
to these cells. ∆LicpaC1::CPA was only half as virulent as
∆LicpaC2::CPA, this may reflect a lower level of LiCPA re-
expression in the first cell line. Alternatively, we could not
exclude that the loss of heterozygocity had not been
accompanied by other re-arrangements destined to help
the parasites to adapt to the higher drug concentration
and consequently that ∆LicpaC1 and ∆LicpaC1::CPA were
less fit than ∆LicpaC2 and ∆LicpaC2::CPA to infect macro-
phages; investigating this will require more sensitive
methods as the level of macrophages infected observed
with the deficient mutants were very low. In contrast, in
vivo experiments did not show any recovery in virulence of
∆LicpaC1::CPA compared with ∆LicpaC1. This is not very
different from the results in human macrophages since
here the virulence of the ∆cpaC1 mutants was also found
to be strongly reduced while the virulence was only partly
restored in ∆cpaC1::CPA  (in contrast to ∆cpaC2::CPA).
One explanation is that the ∆licpaC1::CPA clone expresses
only one LiCPA allele whereas wild type parasites have
two. Also there is dissimilarity between the LiCPA genetic
context in these two cell lines; the 5' LiCPA flank sequence
of both clones was identical, however the nature of the 3'
flank was different in that the re-expressers possessed the
L. major 3' DHFR flank sequence downstream of the
LiCPA gene. Therefore the level of expression of CPA may
not precisely mimic the in vivo situation during the infec-
tion process and during differentiation of promastigote to
amastigote. The DHFR sequence is classically used in
Leishmania constructs to stabilize the mRNA, leading to
higher levels of expression [43,44]. The exact nature of
these key signals is still cryptic and the re-expresser lines
may provide a tool to investigate them.
The results of this study differ in several key respects to
those of Mundodi et al., who described the characterisa-BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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tion of the Lccys2 gene in L. chagasi [45]. Lccys2 [26] is the
functional and syntenic homologue of L. infantum CPA
and differs in sequence at only 6 amino acid positions.
Lccys2 expression is amastigote-specific, yet surprisingly
Mundodi et al. were unable to obtain homozygous null
mutants of Lccys2 in the promastigote life-cycle stage [45].
In contrast, in this study we showed that LiCPA is
expressed in all life-cycle stages analysed and we were able
to generate several independent LiCPA  null mutants,
which were viable as promastigotes in vitro. The efficiency
of transformation can vary between strains of Leishmania
and between species, which might account for the differ-
ences observed in the ability to isolate genetically modi-
fied parasites. Indeed, our studies indicate that L. chagasi
and L. infantum may not be genetically indistinguishable,
as has been proposed [5], but the two species might have
species-specific differences with functional consequences.
It is possible that there have been genome re-arrange-
ments to compensate for the loss of CPA, but these would
be hard to detect. There is likely to be some plasticity in
the genome of different strains of L. infantum, but JPCM5
is a good starting point on which to base further studies
on genetic variation between isolates of the same species.
However, both this study and that of Mundodi et al. iden-
tified the importance of the LiCPA/Lccys2 gene in Leishma-
nia infantum/chagasi infection and pathogenesis.
Conclusion
We provide evidence that the CPA cysteine peptidase is
not essential for replication of L. infantum promastigotes,
but is important for the host-parasite interaction. Deter-
mining the precise roles that LiCPA plays in the intracellu-
lar amastigote stage of the parasite will require further
investigation.
Methods
Parasite lines
L. infantum JPC (MCAN/ES/98/LLM-724) was isolated in
the WHO Collaborating Centre for Leishmaniasis, ISCIII,
Madrid, Spain from the spleen of a naturally-infected dog
residing in the area in 1998. The parasites were main-
tained in Novy-MacNeal-Nicolle (NNN) medium (66%
(v/v) bacto-agar, 33% (v/v) defibrinated rabbit blood) at
28°C. The resulting promastigotes were grown in RPMI
medium before cloning by limiting dilution in agar blood
plates. Five clones were isolated, JPCM1–JPCM5, but all
further analyses were carried out with JPCM5 (MCAN/ES/
98/LLM-877).
Parasite in vitro culture
JPC and JPCM5 promastigotes were grown in modified
Eagle's medium (designated HOMEM medium, RPMI,
SDM79 or NNN media with 10% (v/v) heat-inactivated
foetal calf serum (FCS) at 28°C. Changes between media
were accompanied by temporary elevation of FCS concen-
tration to 20%(v/v). Cultures were sub-passaged to 0.5–1
× 106 cells/ml in fresh medium every 3–4 days when the
culture had reached late logarithmic phase. The exponen-
tial curve regression, the specific growth rate and the dou-
bling time were calculated using Microsoft Excel software
from four independent experiments.
Axenic cultures of amastigote-like forms were performed
in MAA medium following the protocol previously pub-
lished with minor modifications [24]. Briefly, promastig-
otes were grown for 4 to 5 days in HOMEM medium
supplemented with 10% (v/v) FCS and 24.5 mM hemin.
Then 1–5 × 107 parasites were pelleted, washed once in
PBS, re-pelleted and re-suspended in 5 ml of MAA2
medium (modified medium 199 with Hank's salts (Gibco
BRL), 0.5% soybean trypto-casein (Promega), 20% (v/v)
FCS, 4.8 mM L-glutamine, 24.5 mM hemin, 4 mM
NaHCO3 and 25 mM HEPES pH 6.5). The parasites were
then incubated at 37°C in the presence of 5% CO2 for 2
to 3 days before the medium was first changed. Thereafter
the medium was changed every 4 to 5 days.
Transformation from amastigotes to promastigotes was
performed by transferring 106–107  amastigotes, which
were washed once in PBS, into 10 ml of HOMEM medium
supplemented with 20% (v/v) FCS. After incubation at
28°C under air until more than 90% of the parasites were
flagellated (generally after 4 to 5 days), the medium was
changed to HOMEM supplemented with 10% (v/v) FCS.
Parasite transfections and selection
Transfections were performed as previously reported [46]
using 20 µg of linear DNA. 24 h after the transfections,
mutant parasites were selected using one or more antibi-
otics: 20 µg/ml nourseothricin (Hans Knoll Institute, Ger-
many), 50 µg/ml hygromycin B (Roche, Germany), 10 µg/
ml phleomycin (Cayla, France) and/or 20 µg/ml blastici-
din (Cayla, France). Clones were either obtained on 0.7%
agar-HOMEM plates or in liquid medium, in presence of
the appropriate antibiotics, and propagated in HOMEM
medium supplemented with the same antibiotics.
Macrophage infections
The U937 human monocyte line, which is non-adherent,
was differentiated to macrophages in RPMI with 5% (v/v)
FCS supplemented with 0.1 ng/ml phorbol 12-myristate
13-acetate (PMA) at 37°C in presence of 5% CO2. Differ-
entiation had occurred by 72 h when the cell line was
adherent. The cells were washed with RPMI to remove
non-adherent cells before adding the JPCM5 parasites at a
ratio of 1:20 (macrophages:Leishmania). The infected cul-
tures were incubated at 37°C in the presence of 5% CO2.
After 3 hours the cultures were washed to remove free
Leishmania. Samples of infected macrophages were fixed
and stained with Giemsa stain at 24, 48, 72 and 96 h post-BMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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infection. For each time point, at least 100 macrophages
were observed and the number of amastigotes per infected
cell was counted. The results were expressed in terms of
the % infected macrophages and the number of amastig-
otes/infected macrophage.
Infections of the canine monocyte-macrophage cell-line
DH82 were performed essentially as described by Kider-
len and Kaye [47]. Briefly, adherent and non-adherent
DH82 cells were collected in polypropylene round-bot-
tom tubes and stationary phase promastigotes were added
at an effector-to-target ratio of 1:8. The cell suspension
was incubated for 2 hours at 37°C with gentle agitation.
Remaining extra cellular parasites were washed off by dif-
ferential centrifugation (220 × g, 8 min, 4°C, four
repeats); the resulting cell suspension was seeded into 4-
chamber LabTek tissue culture slides (Nunc, Denmark)
and incubated for 120 hours. Slides were stained with
Giemsa solution (Merck, Germany). For each time point
at least 400 macrophages were observed and the number
of amastigotes per infected cell was counted; results were
expressed as the % infected macrophages and the number
of amastigotes/infected macrophage.
Hamster infections
Infections of Golden Syrian hamsters were initiated by
intraperitoneal (i.p.) inoculation with 107  stationary
phase promastigotes in PBS. The hamsters' weight was
monitored every week. The hamsters were sacrificed at 3,
6 and 9 months post-infection and the spleens were
weighed and sliced into pieces to collect amastigote para-
sites. These were transformed in vitro at 28°C in HOMEM
medium supplemented with 20% (v/v) FCS to establish
promastigote cultures.
Hamsters used for the study of parasite virulence were
inoculated i.p. with 108 stationary phase promastigotes
and sacrificed at 1, 3 and 6 months post-infection. Spleen
and liver samples were used for parasite quantification by
culture microtitration [48].
PCR amplification
Genomic DNA was prepared from large scale promastig-
ote cultures and extracted using phenol as previously pub-
lished [21]. PCR was carried out using 50 ng of genomic
DNA as template, 100 ng (about 30 pmoles) of each
primer, 5% DMSO and 2.5 U Taq polymerase (Perkin-
Elmer). Conditions were 1 cycle of 94°C for 5 min then
25 cycles of 94°C for 1 min, 60°C for 2 min and 72°C for
2 min followed by 1 cycle of 72°C for 5 min.
LiCPA deletion and re-expression constructs
JPCM5  CPA  flanking regions were amplified from L.
infantum DNA with primers OL670–OL671 and OL672–
OL673 originally designed to amplify L. mexicana
sequences and integrated in place of the L. mexicana flank
sequences in each side of the DHFR-SAT cassette of the
Lmxcpb-sat deletion construct [22] to generate pGL545.
The LiCPA BLE (pGL726) and HYG (pGL813) deletion
constructs were derived from pGL545 by replacing the
SpeI/BamHI fragment containing the SAT resistance gene
by the appropriate antibiotic resistance gene extracted
from pGL53 and pGL345 (p Lmxcpb-ble and p Lmxcpb-hyg
constructs), respectively. A 1.55 kb DNA fragment corre-
sponding to the LiCPA 5' flank and ORF was amplified
with primers OL1005 and OL1006 in order to generate
SacII and PstI sites for sub-cloning. The LmxCPC 5' and 3'
flank sequences from pGL545 [49] were then replaced by
this PCR product and the LiCPA 3' flank, amplified as
described above, to generate the LiCPA re-expression con-
struct pGL793.
Southern blot analysis
For Southern blot analysis, 5 µg L. infantum genomic DNA
was digested to completion with the appropriate restric-
tion enzymes before being separated and transferred onto
Nylon membrane as described previously [22]. For wild-
type L. infantum DNA analysis, the membrane was treated
and probed with a non-radioactively labelled PCR prod-
uct corresponding to the LiCPA ORF as described above.
∆Licpa  mutant blots were probed with radioactively
labelled PCR products corresponding to the LiCPA ORF 5'
or 3' flanks, essentially as published [50] except that the
membranes, after high stringency washes, were exposed
on Phosphorimager plates. The plates were scanned at
high resolution on a Typhoon 8600 apparatus (Molecular
Dynamics).
Northern blot analysis
Total RNA was extracted from 107 to 108 parasites using
Trizol (Invitrogen, UK) or RNAEasy kit (Qiagen, Ger-
many) according to the manufacturer's instructions. The
amount of total RNA extracted was quantified by spectro-
photometry and 5 µg were loaded on 0.8% agarose gel
prepared in DEPC-treated 0.5× TBE buffer. After separa-
tion, gels were washed once in DEPC-water and trans-
ferred onto membrane using to the same procedure as for
Southern blot. Hybridization with radioactively labelled
probes took place overnight at 65°C. Stringent washes
were performed in 0.2× SSC, 0.1% SDS and the mem-
branes were exposed onto Phosphorimager plates. The
plates were scanned at high resolution after two days
exposure.
RT-PCR
cDNA was prepared from 5 µg of total RNA using the AMV
RT module from the GeneRacer kit (Invitrogen, UK). A
first RT-PCR was performed on 1 µl of cDNA mixture with
2 units of Thermozyme enzyme (Invitrogen, UK) and 100
ng of first-round primers in 50 µl reaction volume. TheBMC Molecular Biology 2006, 7:42 http://www.biomedcentral.com/1471-2199/7/42
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resulting PCR mixture was diluted 30 times in water and
1 µl of it was used as template for a nested reaction per-
formed in a 20 µl reaction volume with 1 unit of TaqDNA
polymerase (ABGene, UK) and 100 ng of nested primers.
The first-round primers used were the Splice Leader
primer (OL618)/OL137 for the 5' amplification, and
OL67/GeneRacer Oligo dT primer for the 3' amplification.
The primers for the nested PCR were OL618/OL136 for
the 5' amplification and OL1194/GeneRace 3' Nested
primer for the 3' amplification. OL1984 and OL1985 were
used to PCR amplify LinJ36.2050.
Oligonucleotides used in this study.
OL67 5'-CAGAACATGCAGACAGCC-3'
OL136 5'-GAGCGGAACCGTAGCACA-3'
OL137 5'-GACAGCGTCCGCAGTGGTG-3'
OL618 5'-AAGTATCAGTTTCTGTACTTTATG-3'
OL670 5'-ATATAAGCTTCTACTGCACCAGGTACTG-3'
OL671 5'-ACGTGTCGACGAGAAGGACGTGACGGGG-3'
OL672 5'-GGTGCCCGGGGCTGTGCACAAACACGACC-
3'
OL673 5'-GTCGAGATCTCACTGTCCATGGCACGCCTG-
3'
OL1006 5'-CTGCAGCTAGGCCGCTGTCGTCGG-3'
OL1194 5'-GACAGCGTCCGCAGTGGTG-3'
OL1984 5'-GCACCCGGGATGGCGGCAACTCATCTTAC-
3'
OL1985 5'-GCAGGATCCTCACTTCGGCAAACCGT-
TCTTTC-3'
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